Nanoparticles that target nonamyloid and nontau pathways in Alzheimer’s disease
Firoozeh Alavian, Arefeh Hajimohammadi · 2026
Read Nanoparticles that target nonamyloid and nontau pathways in Alzheimer’s disease by Firoozeh Alavian, Arefeh Hajimohammadi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13280311.txt.
Description
Firoozeh Alavian and Arefeh Hajimohammadi give a 2026 review of nanoparticles that target Alzheimer pathways past amyloid and tau. Alzheimer disease is a complex brain decay illness. Two protein clumps, amyloid and tau, dominate past drug hunts. Swelling, power core flaws and lysosome faults, where lysosomes are cell recycling sacs, offer fresh paths. Nanoparticles can cross the blood brain barrier and aim at set targets.
Lipid, chitosan and gold particles carried anti swelling and antioxidant compounds like curcumin and resveratrol in animal studies. Those loads cut brain swelling and boosted power core function. Particles tagged for mitochondria, the power cores, cut rust stress and raised energy output. Polymer and carbon structures aided lysosome function and cell balance. All proof stays preclinical, in animals and dishes, so human trials must still prove worth.
Catalog record
| CREATOR | Firoozeh Alavian, Arefeh Hajimohammadi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 148100 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |